Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta treatment for multiple sclerosis: persisting questions

D E Goodkin1

  • 1UCSF/MT Zion Multiple Sclerosis Center, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.

Journal of neurology, neurosurgery, and psychiatry·2003
Same author

T2 relaxation time histograms in multiple sclerosis.

Magnetic resonance imaging·2003
Same author

3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain.

Magnetic resonance imaging·2002
Same author

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Neurology·2002
Same author

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Neurology·2002
Same author

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis.

Journal of consulting and clinical psychology·2002

Interferon treatments for multiple sclerosis (MS) show benefits in reducing relapses and lesions. Further research is needed to address remaining questions on efficacy, antibodies, and optimal use of these MS therapies.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon therapies are commonly used to manage relapsing forms of MS.
  • Placebo-controlled trials provide evidence for the efficacy of specific interferon treatments.

Purpose of the Study:

  • To review and synthesize findings from clinical trials of interferon beta-1b and interferon beta-1a in relapsing MS.
  • To evaluate the effectiveness of these treatments in reducing disease activity and disability progression.
  • To identify remaining questions and areas for further investigation regarding interferon therapy in MS.

Main Methods:

  • Review of placebo-controlled, double-masked clinical trials for interferon beta-1b (Betaseron) and interferon beta-1a (Avonex).

Related Experiment Videos

  • Analysis of data on exacerbation rates, MRI lesion burden (T2-weighted and gadolinium-enhancing), and physical disability accumulation.
  • Consideration of factors such as route of administration and antibody formation.

    • Main Results:

    • Interferon beta-1b (subcutaneous, every other day) significantly reduces exacerbation rates and T2 lesion area in relapsing-remitting MS.
    • Interferon beta-1a (intramuscular, weekly) significantly reduces exacerbation rates, new focal gadolinium-enhanced lesions, and slows disability accumulation.
    • Both agents demonstrate efficacy in managing key aspects of relapsing MS disease activity.

    Conclusions:

    • Interferon beta therapies offer significant benefits for patients with relapsing multiple sclerosis.
    • Further research is warranted to fully understand treatment efficacy, antibody responses, optimal dosing, and administration routes.
    • Critical reviews of ongoing and future trials are necessary to refine therapeutic strategies for MS.